Monograph Details
|
|
Immune System
> Immunomodulators
|
|
SYNAGIS |
| Manufacturer |
|
MedImmune, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antiviral monoclonal antibody (IgG1K). |
| Generic Name |
|
Palivizumab 50mg/vial, 100mg/vial; pwd for IM inj after reconstitution; liq soln; preservative-free. |
| Indications |
|
Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease (eg, infants with bronchopulmonary dysplasia or born ≤35 wks gestational age), or children with hemodynamically significant congenital heart disease). |
| Children |
|
Give by IM injection into anterolateral thigh. 15mg/kg once per month before and during RSV season. Cardiopulmonary bypass: see literature. Divide doses >1mL into 2 inj sites. |
| Adults |
|
Not applicable. |
| Precautions |
|
Have epinephrine (1:1000) inj available. Pregnancy (Cat.C). |
| Adverse Reactions |
|
Anaphylaxis, hypesensitivity reactions, upper respiratory infection/symptoms (eg, fever, wheezing), GI disturbances, otitis media, rash, hernia, increased SGOT. |
| How Supplied |
Single-use vials (pwd)—1
Single-use vials (soln)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
